Thoracic Oncology
With over 25 years’ experience, Dr. Julie Brahmer is a highly compassionate and dedicated medical professional, whose career was inspired by the care her grandfather received after he was diagnosed with Non-Hodgkin Lymphoma.
Dr. Brahmer’s academic career began with the study of Philosophy and Chemistry in 1989 at the Creighton University in Omaha, Nebraska. She then went on to pursue her Medical Degree at the University of Nebraska Medical Center, graduating in 1993. Following this, she secured an internship at the University of Utah in Salt Lake City focusing on Internal Medicine where she advanced to serve as the Chief Medical Resident from 1996-1997. After submitting applications to a variety of medical institutions, she accepted a Fellowship position at John Hopkins School of Medicine, where she would remain loyal throughout the course of her medical career. Among her many accomplishments, she received her Board Certification in Medical Oncology by the American Board of Internal Medicine.
Dr. Brahmer is currently the Director of the Thoracic Oncology Program and Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center. In addition, she is the co-principal investigator of John Hopkins National Clinical Trials Network and is the Director of the Kimmel Cancer Center on the John Hopkins Bayview campus. In the highly prestigious roles that she holds, she specializes in Lung Cancer, Clinical Trials, Mesothelioma, and Medical Oncology. As Director of the Thoracic Oncology Group and the Co-Director of John Hopkins Cancer Immunology National Cancer Institute sponsored program, beyond her many responsibilities of conducting research, working long hours in the clinic, and administrative work, she is a mentor to her fellow faculty members and oncology fellows which she finds to be exceptionally rewarding.
Dr. Brahmer’s medical research to date has centered on immunotherapy of anti-programmed cell death protein 1 (PD-1) antibodies, investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies and international phase III studies of immunotherapies in lung cancer, thoracic malignancies drug development and the development of anti-PD-1 antibodies. She is committed to helping develop treatments for mesothelioma and lung cancer through her role as Active Clinical Leader and is also heavily involved in the organization of the Thoracic Oncology Disease Management Team at Johns Hopkins.
Dr. Brahmer is a Founding Board Member of the National Lung Cancer Partnership (now known as the Lung Cancer Research Foundation) and is actively involved with LUNGevity and the Lung Cancer Research Foundation of America on their respective Medical Scientific Advisory Boards. In addition, she is affiliated with a number of other medical associations including the American Association for Cancer Research, the American Society of Clinical Oncology, the Eastern Cooperative Oncology Group (ECOG-ACRIN) Thoracic Cancer Committee, and the Society for Immunotherapy of Cancer, and the International Association for the study of Lung Cancer.
Looking to the future, Dr. Brahmer plans to continue working in the field of Oncology, both in her daily roles and through her various associations and advisory roles. She is committed to helping in the fight against cancer and knowing that she is actively contributing to this cause gives her immense satisfaction and fuels her the motivation to continue her work for many years to come.